Androgen receptor-related non-coding RNAs in prostate cancer
Prostate cancer (PCa) is the second leading cause of cancer-related death among men in
the United States. Androgen receptor (AR) signaling is the dominant oncogenic pathway in …
the United States. Androgen receptor (AR) signaling is the dominant oncogenic pathway in …
Targeting PRAS40: a novel therapeutic strategy for human diseases
Q Zhou, S Tang, X Zhang, L Chen - Journal of Drug Targeting, 2021 - Taylor & Francis
Proline-rich Akt substrate of 40 kD (PRAS40) is not only the substrate of protein kinase B
(PKB/Akt), but also the binding protein of 14-3-3 protein. PRAS40 is expressed in a variety of …
(PKB/Akt), but also the binding protein of 14-3-3 protein. PRAS40 is expressed in a variety of …
Differential expression of miRNAs contributes to tumor aggressiveness and racial disparity in African American men with prostate cancer
Simple Summary Prostate cancer (PCa) is the leading cancer in incidence and second
leading cause of cancer mortality in US men. Recent data showed a 3% increase in PCa …
leading cause of cancer mortality in US men. Recent data showed a 3% increase in PCa …
[HTML][HTML] LncRNA MIR205HG regulates melanomagenesis via the miR-299-3p/VEGFA axis
J Guo, Q Gan, C Gan, X Zhang, X Ma, M Dong - Aging (Albany NY), 2021 - ncbi.nlm.nih.gov
In this study, we investigated the role of lncRNA MIR205HG in melanomagenesis.
Quantitative real-time PCR (qRT-PCR) analysis showed that MIR205HG levels were …
Quantitative real-time PCR (qRT-PCR) analysis showed that MIR205HG levels were …
Advanced therapeutic options for treatment of metastatic castration resistant prostatic adenocarcinoma
The initial stage of prostatic adenocarcinoma (PaC) has been treated with surgery and
radiation therapy, but the advanced stages need systemic novel treatment. Since 2010 …
radiation therapy, but the advanced stages need systemic novel treatment. Since 2010 …
miR‑589‑3p sponged by the lncRNA TINCR inhibits the proliferation, migration and invasion and promotes the apoptosis of breast cancer cells by suppressing the Akt …
F Guo, X Zhu, Q Zhao, Q Huang - … journal of molecular …, 2020 - spandidos-publications.com
The long non‑coding (lnc) RNA named tissue differentiation inducing non‑protein coding
RNA (TINCR) is a tumor marker that has not been studied in breast cancer. The present …
RNA (TINCR) is a tumor marker that has not been studied in breast cancer. The present …
Anticancer function of microRNA‐30e is mediated by negative regulation of HELLPAR, a noncoding macroRNA, and genes involved in ubiquitination and cell cycle …
K Ganapathy, C Ngo, T Andl, D Coppola… - Molecular …, 2022 - Wiley Online Library
Prostate cancer (PCa) progression relies on androgen receptor (AR) function, making AR a
top candidate for PCa therapy. However, development of drug resistance is common, which …
top candidate for PCa therapy. However, development of drug resistance is common, which …
Interaction between non-coding RNAs and androgen receptor with an especial focus on prostate cancer
The androgen receptor (AR) is a member of the nuclear receptor superfamily and has three
functional domains, namely the N-terminal, DNA binding, and C-terminal domain. The N …
functional domains, namely the N-terminal, DNA binding, and C-terminal domain. The N …
Non-coding RNAs set a new phenotypic frontier in prostate cancer metastasis and resistance
J Altschuler, JA Stockert, N Kyprianou - International Journal of Molecular …, 2021 - mdpi.com
Prostate cancer (PCa) mortality remains a significant public health problem, as advanced
disease has poor survivability due to the development of resistance in response to both …
disease has poor survivability due to the development of resistance in response to both …
Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p
RH Barbier, EM McCrea, KY Lee, JD Strope… - Scientific reports, 2021 - nature.com
Understanding mechanisms of resistance to abiraterone, one of the primary drugs approved
for the treatment of castration resistant prostate cancer, remains a priority. The organic anion …
for the treatment of castration resistant prostate cancer, remains a priority. The organic anion …